


# S-Aroylthiooximes: A Facile Route to Hydrogen Sulfide Releasing Compounds with Structure-Dependent Release Kinetics

Jeffrey C. Foster, Chadwick R. Powell, Scott C. Radzinski, and John B. Matson\*

Department of Chemistry, Virginia Tech, Blacksburg, Virginia 24061, United States

**S** Supporting Information

**ABSTRACT:** We report the facile preparation of a family of S-arylothiooxime (SATO) H<sub>2</sub>S donors, which are synthesized via a click reaction analogous to oxime formation between S-arylothiohydroxylamines (SATHAs) and aldehydes or ketones. Analysis of cysteine-triggered H<sub>2</sub>S release revealed structure-dependent release kinetics with half-lives from 8–82 min by substitution of the SATHA ring. The pseudo-first-order rate constants of substituted SATOs fit standard linear free energy relationships ( $\rho = 1.05$ ), demonstrating a significant sensitivity to electronic effects.




Gasotransmitters such as hydrogen sulfide (H<sub>2</sub>S) are endogenous signaling gases that are enzymatically produced and have specific physiological functions,<sup>1</sup> and delivery of these gasotransmitters can be exploited for therapeutic applications.<sup>2</sup> The therapeutic potential of H<sub>2</sub>S is vast, with promising preclinical studies conducted on several diseases and disorders. For example, H<sub>2</sub>S exhibits cardioprotection through vasorelaxation,<sup>3</sup> suppresses oxidative stress,<sup>4</sup> reduces inflammation in the brain,<sup>5</sup> and protects the liver in ischemia-reperfusion events,<sup>6</sup> among other effects. Unfortunately, H<sub>2</sub>S lags behind the other gasotransmitters (NO and CO) in studies on its physiological role and translational potential. Versatile H<sub>2</sub>S-releasing functional groups are needed to unlock this untapped potential and elevate the status of this gasotransmitter.

The study of H<sub>2</sub>S physiology is accomplished through the use of various H<sub>2</sub>S organic and electrochemical sensors<sup>7</sup> in conjunction with H<sub>2</sub>S-releasing compounds (we refer to H<sub>2</sub>S, HS<sup>-</sup>, and S<sup>2-</sup> collectively here as H<sub>2</sub>S, although all three species are in a protonation equilibrium in aqueous solution). Most studies on H<sub>2</sub>S physiology and biology have been done with sulfide salts (Na<sub>2</sub>S and NaHS). Organic H<sub>2</sub>S donors have recently been developed, but most suffer a number of limitations including structural constraints and uncontrolled H<sub>2</sub>S release kinetics.<sup>8</sup> The *in vivo* function of H<sub>2</sub>S is coupled to its local concentration;<sup>9</sup> therefore, precise control over the rate of H<sub>2</sub>S release from donor compounds is paramount.

S-Aroylthiohydroxylamines (SATHAs) have been used in the synthesis of H<sub>2</sub>S-releasing *N*-(benzoylthio)benzamides.<sup>8d</sup> As sulfur-containing analogs to acylhydrazides and acylhydroxylamines, thiohydroxylamines are reported to undergo condensation reactions with both aldehydes and ketones to form thiooximes, a functional group that has received little attention in the literature.<sup>10</sup> We hypothesized that S-arylothiooximes (SATOs) might react with cysteine to generate H<sub>2</sub>S in a similar manner to previously reported compounds.<sup>8d</sup> Given the

simplicity and robust nature of oxime and hydrazone-forming reactions, SATO formation could provide a method for attaching an H<sub>2</sub>S-releasing functionality to many types of compounds under mild conditions. Herein, we report a synthetic strategy for accessing a variety of H<sub>2</sub>S-releasing compounds via a thiooxime click reaction analogous to oxime formation. Additionally, we explore the reactivity and H<sub>2</sub>S-releasing capacity of this unique functional group.

In order to evaluate our hypothesis, we synthesized a series of SATOs from substituted SATHAs and commercially available aldehydes and ketones (Scheme 1). SATHAs were


**Scheme 1. Synthesis of SATOs**

prepared by previously described methods with a range of substituents.<sup>11</sup> Thiooxime formation reactions were conducted at equimolar concentrations of SATHA and aldehyde/ketone in CH<sub>2</sub>Cl<sub>2</sub> in the presence of a catalytic quantity of trifluoroacetic acid and molecular sieves.

The versatility of thiooxime formation was demonstrated by mixing unsubstituted SATHA (R<sub>2</sub> = H) with several aldehydes and ketones (Table 1) to generate compounds **1a–1j**. Aldehyde-derived SATOs (**1a–1g**) were synthesized with high conversions and high isolated yields. Ketone-derived SATOs (**1h–1j**) were somewhat more difficult to make. Condensation of SATHA with a number of aliphatic aldehydes and ketones was attempted; however, only one aliphatic SATO, derived from pivalaldehyde (**1g**), could be isolated due to rapid

Received: December 16, 2013

Published: February 27, 2014

**Table 1. Conversion and Hydrolysis Kinetics of Substituted SATOs**


compd	R <sub>1</sub> , Y	% conversion <sup>a</sup>	t <sub>1/2</sub> hydrolyt. <sup>b</sup> (h)
1a	Ph, H	>99	44
1b	<i>p</i> -Ph-F, H	>99	76
1c	<i>p</i> -Ph-COOH, H	>99	58
1d	<i>p</i> -Ph-OCH <sub>3</sub> , H	90	57
1e	furanyl, H	>99	221
1f	cinnamyl, H	>99	118
1g	C(CH <sub>3</sub> ) <sub>3</sub> , H	74	1.0
1h	Ph, CH <sub>3</sub>	66	199
1i	<i>p</i> -Ph-F, CH <sub>3</sub>	87	266
1j	<i>p</i> -Ph-OCH <sub>3</sub> , CH <sub>3</sub>	37	194


<sup>a</sup>Conversion to SATO as determined by relative integration of thiooxime to aldehyde/ketone signals by <sup>1</sup>H NMR. <sup>b</sup>Hydrolysis conducted in 20% (v/v) ACN in PBS (pH = 7.4) at rt.

hydrolysis. We also prepared SATOs with substituents (R<sub>2</sub>) on the SATHA ring at near complete conversion.

For the set of ketones studied (1h–1j), conversion increases with increasing electron withdrawal. These results are consistent with well-known linear free energy relationships.<sup>12</sup> The maximum conversion attained for several substituted SATOs is summarized in Table 1.

Two pathways can be envisioned for generating H<sub>2</sub>S from SATOs (Scheme 2). Pathway A involves addition of the

### Scheme 2. Possible Routes of H<sub>2</sub>S Generation



cysteine thiol to the SATO acyl group followed by rapid S→N acyl transfer in a step similar to native chemical ligation.<sup>13</sup> In this case, the arylidenethiooxime would form, which could decompose to generate the original ketone or aldehyde along with H<sub>2</sub>S and NH<sub>3</sub>, as has been previously noted for similar substrates.<sup>8d</sup> Pathway B describes an initial hydrolysis step, which would generate the SATHA and the ketone or aldehyde used to make the SATO. (In preliminary experiments, unsubstituted SATHA released H<sub>2</sub>S in the presence of cysteine, leading to the same products as proposed for Pathway A.)


While both pathways lead to H<sub>2</sub>S release, Pathway A would be more desirable for functionalizing substrates to make prodrugs, where H<sub>2</sub>S would be released simultaneously with the drug. Considering the tunable hydrolysis kinetics of the analogous oxime functional group, Pathway B could be discouraged by controlling steric and electronic factors of the SATO bond. Additionally, the rate of H<sub>2</sub>S release could be precisely controlled by manipulating the electronics of the SATHA ring because a likely rate-limiting step would be the

breakdown or formation of a tetrahedral intermediate at the aryl carbon.

To achieve H<sub>2</sub>S production via Pathway A, the rate of hydrolysis (Pathway B) must be slow relative to the rate of H<sub>2</sub>S release from reaction with cysteine. Hydrolysis of compounds 1a–1j was evaluated using absorbance spectroscopy (Figure S6). In these experiments, the concentration of the SATOs relative to their hydrolysis products (SATHA and ketone or aldehyde) was determined over multiple half-lives. In general, SATOs hydrolyzed with half-lives in the time scale of days for compounds 1a–1j excluding 1g (Table 1).

The hydrolysis of SATOs followed first-order kinetics but did not conform to the expected linear free energy trend.<sup>14</sup> The unsubstituted compound (1a) hydrolyzed faster than the –F, –COOH, and –OCH<sub>3</sub> functionalized compounds (1b, 1c, and 1d). This type of behavior has been observed in other systems.<sup>15</sup> The ketone-derived SATOs hydrolyzed more slowly and showed a stability order of 1i > 1h > 1j.

To evaluate our ability to control the rate of H<sub>2</sub>S release from SATOs, we measured H<sub>2</sub>S release using two different methods: (1) a microelectrode-based method that gives real-time data on H<sub>2</sub>S concentration and (2) a colorimetric method that is better suited for longer release periods and was used to determine the half-life of H<sub>2</sub>S release for specific compounds (Figure 1).




**Figure 1.** (A) Representative H<sub>2</sub>S release curve of 1a measured by the microelectrode method and (B) kinetics as measured by the methylene blue spectrophotometric method (10–200 min with intensity increasing over time). Inset shows the kinetics plot derived from absorbances measured at 676 nm. Experiments were conducted in triplicate.

Additionally, the colorimetric method allowed for determination of H<sub>2</sub>S release kinetics from compounds that were insoluble in the conditions required for the microelectrode experiments (1l–1n).


For the microelectrode experiments, SATOs 1a–1j, 1k, and 1o–1p were dissolved in THF and added to buffered solutions containing 1 mM cysteine. Upon addition of the SATO, H<sub>2</sub>S release was monitored continuously with an H<sub>2</sub>S-selective microelectrode (Figure 1A). The H<sub>2</sub>S concentration reached a maximum value, which is defined as the peaking time (Tables 2 and 3), after which it began to decrease as the result of volatilization and oxidation by O<sub>2</sub>.<sup>7</sup>

In general, substitution at the *para* position of the arylaldehyde/ketone ring (1a–1d) has little effect on H<sub>2</sub>S release rate (Table 2). Although the rate of H<sub>2</sub>S release does not exhibit a strong dependence on the electronics of the substituent on the arylaldehyde ring, the rate of hydrolysis is influenced by substitution at this position. Taken together,

Table 2. H<sub>2</sub>S Release from Substituted SATOs


compd	peaking time (min) <sup>a</sup>	compd	peaking time (min) <sup>a</sup>
1a	24 ± 2	1f	26 ± 3
1b	20 ± 2	1g	27 ± 2
1c	18 ± 1	1h	34 ± 2
1d	22 ± 3	1i	34 ± 1
1e	14.8 ± 0.3	1j	33.5 ± 0.9

<sup>a</sup>Time after which [H<sub>2</sub>S] reached a maximum value using an H<sub>2</sub>S sensitive microelectrode. Studies were conducted at 40 μM SATO in 0.1% THF in PBS buffer (pH = 7.4) at rt in the presence of 1 mM cysteine.

Table 3. H<sub>2</sub>S Release from Substituted SATOs


R <sub>2</sub>	peaking time (min) <sup>a</sup>	t <sub>1/2</sub> H <sub>2</sub> S release (min) <sup>b</sup>
H (1a)	24 ± 2	34 ± 6
F (1k)	21 ± 2	29 ± 2
Cl (1l)	— <sup>c</sup>	18 ± 1
CF <sub>3</sub> (1m)	— <sup>c</sup>	11 ± 1
CN (1n)	— <sup>c</sup>	8 ± 1
CH <sub>3</sub> (1o)	33.7 ± 0.4	52.9 ± 1.4
OCH <sub>3</sub> (1p)	36 ± 3	82 ± 11

<sup>a</sup>Time after which [H<sub>2</sub>S] reached a maximum value detected by an H<sub>2</sub>S sensitive microelectrode. Studies were conducted at 40 μM SATO in 0.1% THF in PBS buffer (pH = 7.4) at rt in the presence of 1 mM cysteine. <sup>b</sup>Half-lives of release were measured by using the methylene blue assay at 100 μM SATO in 30% THF in PBS buffer (pH = 7.4) at rt in the presence of 1 mM cysteine. <sup>c</sup>Samples were not soluble in the media for the microelectrode probe assay.

these data suggest that the stability of SATOs can be tuned without drastically altering the H<sub>2</sub>S release profile.

We also tested several other molecules as triggers for H<sub>2</sub>S release (Figure S2). Glutathione was shown to trigger H<sub>2</sub>S release at levels similar to the case of cysteine, while *N*-acetylcysteine was found to trigger H<sub>2</sub>S generation at a slower rate than cysteine. However, neither lysine nor serine triggered H<sub>2</sub>S release, nor was H<sub>2</sub>S generation observed in aqueous solutions of SATO in the absence of thiol functionality. Additionally, H<sub>2</sub>S release was evaluated at different cysteine concentrations. In general, higher concentrations of cysteine resulted in an increased H<sub>2</sub>S release rate (Figure S3). H<sub>2</sub>S generation was also observed in plasma (Figure S5).

The colorimetric method of measuring the concentration of H<sub>2</sub>S involves the H<sub>2</sub>S-promoted conversion of *N,N*-dimethyl-*p*-phenylenediamine into methylene blue,<sup>16</sup> which can be measured by its peak absorbance at 676 nm (Figure 1B). As real-time detection is not possible with the methylene blue method, time points are taken at various intervals for each compound. We note that the methylene blue method can overestimate H<sub>2</sub>S levels, so we make no attempt here to translate our measurements to actual H<sub>2</sub>S concentrations.<sup>17</sup>

Half-lives for the pseudo-first-order kinetic plots were determined (Figure 1B inset) and found to be on the order of 8–82 min. In general, results were similar to the electrochemical method, with H<sub>2</sub>S release half-lives trending based on SATHA ring substituent electronics. A Hammett plot was constructed to quantify the effect of substituents on the rate of H<sub>2</sub>S release (Figure 2). The Hammett plot revealed a





Figure 2. Hammett plot of the rate of H<sub>2</sub>S release relative to 1a vs the  $\sigma$  value of the *p*-substituent ( $\rho = 1.05$ ,  $R^2 = 0.986$ ).

strong dependence of the rate of H<sub>2</sub>S release on the  $\sigma$  values of the SATHA substituents ( $\rho = 1.05$ ). It follows from Figure 2 that the H<sub>2</sub>S release kinetics of SATOs can be finely tuned. The strong correlation between H<sub>2</sub>S release rate and  $\sigma$  suggests that the rate of H<sub>2</sub>S release for other SATOs could be predicted from the Hammett plot. These data represent an unprecedented level of control over the rate of H<sub>2</sub>S release.

The fast reaction between SATOs and cysteine to generate H<sub>2</sub>S ( $t_{1/2} \approx 8$ –82 min) compared with their hydrolysis rate ( $t_{1/2} \approx 45$ –250 h) rules out pathway B as the operative H<sub>2</sub>S release mechanism for most SATOs under the conditions tested. To study the mechanism of H<sub>2</sub>S release, the products of the reaction between 1a and cysteine were analyzed. Based on the compounds isolated by HPLC, we propose that H<sub>2</sub>S may be generated according to Scheme 3. First, reversible thiol

Scheme 3. Proposed Mechanism of H<sub>2</sub>S Release<sup>a</sup>

<sup>a</sup>Boxed products were either isolated from the reaction mixture or detected indirectly.

exchange between the SATO and cysteine gives the arylidene-thiooxime along with *N*-benzoylated cysteine after a *S* → *N* acyl transfer step. Reaction of a second equivalent of cysteine with the arylidene-thiooxime generates thiocysteine, ammonia, and the original aldehyde. Thiocysteine then reacts with another equivalent of cysteine to generate cysteine and H<sub>2</sub>S.<sup>18</sup> Further mechanistic work is needed to evaluate whether this is the

operative mechanism for H<sub>2</sub>S release. See the Supporting Information for further discussion.

Regardless of the pathway of H<sub>2</sub>S release, the parent aldehyde/ketone is regenerated in the process. This implies that SATHA can be conjugated to aldehyde- or ketone-bearing therapeutic agents such as cinnamaldehyde (as in **1f**), known to possess antimicrobial<sup>19</sup> and anticancer<sup>20</sup> properties, to impart tandem physiological activity. However, the requirement for a ketone or aldehyde limits the types of drugs amenable to this type of derivatization to those bearing these functionalities. H<sub>2</sub>S donor-drug hybrids such as NOSH-aspirin<sup>8a</sup> and H<sub>2</sub>S-releasing derivatives of diclofenac<sup>9</sup> have been reported and in many cases show improved physiological responses compared with their parent drugs.

In summary, we have synthesized a series of SATOs from SATHAs and common aldehydes and ketones. We showed that SATOs are relatively stable in aqueous solution at physiological pH, and hydrolysis of these compounds can be controlled to a degree by tuning the steric and electronic factors of the SATO bond. We demonstrated that the half-life of H<sub>2</sub>S release could be varied between 8 and 82 min simply by changing the substituent on the SATHA ring. Given the ease of installation of this versatile functional group, we envision that SATOs could open new avenues for the study of H<sub>2</sub>S biology and could enable a new generation of H<sub>2</sub>S-releasing therapeutics and H<sub>2</sub>S-drug conjugates.

## ■ ASSOCIATED CONTENT

### Supporting Information

Synthetic details, characterization data, and kinetics plots. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: [jbmatson@vt.edu](mailto:jbmatson@vt.edu)

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This work was supported by the Institute for Critical Technology and Applied Science (JFC12-256). We thank Prof. Richard D. Gandour (Virginia Tech) for helpful discussions and Prof. Amanda J. Morris (Virginia Tech) and Prof. Tijana Z. Grove (Virginia Tech) for use of instruments.

## ■ REFERENCES

- (1) Mustafa, A. K.; Gadalla, M. M.; Snyder, S. H. *Sci. Signal.* **2009**, *2*, re2.
- (2) (a) Motterlini, R.; Otterbein, L. E. *Nat. Rev. Drug. Discov.* **2010**, *9*, 728–743. (b) Carpenter, A. W.; Schoenfisch, M. H. *Chem. Soc. Rev.* **2012**, *41*, 3742–3752. (c) Wang, R. *Physiol. Rev.* **2012**, *92*, 791–896.
- (3) Hosoki, R.; Matsuki, N.; Kimura, H. *Biochem. Biophys. Res. Commun.* **1997**, *237*, 527–531.
- (4) Kimura, Y.; Dargush, R.; Schubert, D.; Kimura, H. *Antioxid. Redox Signaling.* **2006**, *8*, 661–670.
- (5) Lee, M.; Sparatore, A.; Del Soldato, P.; McGeer, E.; McGeer, P. L. *Glia.* **2010**, *58*, 103–113.
- (6) Jha, S.; Calvert, J. W.; Duranski, M. R.; Ramachandran, A.; Lefer, D. J. *Am. J. Physiol.* **2008**, *295*, H801–H806.
- (7) Hughes, M. N.; Centelles, M. N.; Moore, K. P. *Free Radical Biol. Med.* **2009**, *47*, 1346–1353.

- (8) (a) Kodela, R.; Chattopadhyay, M.; Kashfi, K. *ACS Med. Chem. Lett.* **2012**, *3*, 257–262. (b) Devarie-Baez, N. O.; Bagdon, P. E.; Peng, B.; Zhao, Y.; Park, C.-M.; Xian, M. *Org. Lett.* **2013**, *15*, 2786–2789. (c) Lee, Z. W.; Zhou, J.; Chen, C.-S.; Zhao, Y.; Tan, C.-H.; Li, L.; Moore, P. K.; Deng, L.-W. *PLoS One* **2011**, *6*, e21077. (d) Zhao, Y.; Wang, H.; Xian, M. *J. Am. Chem. Soc.* **2011**, *133*, 15–17.
- (9) Wallace, J. L. *Trends Pharmacol. Sci.* **2007**, *28*, 501–505.
- (10) Barton, D. H. R.; Magnus, P. D.; Pennanen, S. I. *J. Chem. Soc., Chem. Commun.* **1974**, 1007.
- (11) Raasch, M. S. *J. Org. Chem.* **1972**, *37*, 3820–3823.
- (12) Hammett, L. P. *J. Am. Chem. Soc.* **1937**, *59*, 96–103.
- (13) Dawson, P. E. *Israel J. Chem.* **2011**, *51*, 862–867.
- (14) Gregory, B. J.; Moodie, R. B. *J. Chem. Soc. B* **1970**, 862–866.
- (15) Stein, A. R.; Tencer, M.; Moffatt, E. A.; Dawe, R.; Sweet, J. J. *Org. Chem.* **1980**, *45*, 3539–3540.
- (16) Siegel, L. M. *Anal. Biochem.* **1965**, *11*, 126–132.
- (17) Olson, K. R. *BBA-Bioenergetics.* **2009**, *1787*, 856–863.
- (18) Mueller, E. G. *Nat. Chem. Biol.* **2006**, *2*, 185–194.
- (19) Ali, S.; Khan, A.; Ahmed, I.; Musaddiq, M.; Ahmed, K.; Polasa, H.; Rao, L.; Habibullah, C.; Sechi, L.; Ahmed, N. *Ann. Clin. Microbiol. Antimicrob.* **2005**, *4*, 1–7.
- (20) Cabello, C. M.; Bair Iii, W. B.; Lamore, S. D.; Ley, S.; Bause, A. S.; Azimian, S.; Wondrak, G. T. *Free Radical Biol. Med.* **2009**, *46*, 220–231.